Delivra Inc. Selected as Funding Recipient from the Canadian Federal Government (ACOA) to Fund Research and Development of Its Delivery System
Canadian Prime Minister Steven Harper presented the investment from the Atlantic Canada Opportunities Agency (ACOA) to Delivra, Inc. CEO Dr. Joseph Gabriele
BURLINGTON, ON, May 15, 2013 /CNW/ - Delivra, Inc., the Canadian-based manufacturer and market leader in transdermal delivery technology, announces the investment from the Atlantic Canada Opportunities Agency (ACOA). The $2.86 million investment from ACOA's core funding program, Atlantic Innovation Fund (AIF), enables Delivra, Inc. to strengthen and expand its novel delivery system Delivra™ through research and development. Canadian Prime Minister Steven Harper personally presented Delivra, Inc. CEO Dr. Joseph Gabriele with the investment.
Minister Gail Shea described the investment in terms of shaping Atlantic Canada's knowledge economy, "Our Government is focused on jobs, growth and long-term prosperity. By investing in R&D and innovative companies like Delivra Inc., we will position Atlantic Canada to succeed in the knowledge economy of the 21st century by building more productive, globally competitive companies. These companies will create wealth, more jobs and a greater quality of life in our region."
"This investment by the Atlantic Innovation Fund will allow our innovative Canadian company to hire full time employees on Prince Edward Island. This enables us to implement, validate and commercialize the cutting edge science behind our
non- prescription transdermal cream products distributed nationally through pharmacy . Specifically, AIF's funding will be instrumental to improve health and wellness for those suffering from inflammatory and other disease states," commented Dr. Joseph Gabriele.
Delivra™, the unique Canadian-born technology behind LivRelief and LivSport therapeutic creams, has improved the lives of thousands of patients in addition to providing a safer alternative to oral medication such as pain relief medications. The investment from AIF will allow Delivra, Inc. to expand the scope of use beyond its current applications. Delivra products are currently available in the U.S. and Canada, with additional interest from around the world.
About the Atlantic Innovation Fund
Since its launch in 2001, the Atlantic Innovation Fund (AIF) has been helping Atlantic Canadians compete in a global knowledge-based economy through the development and commercialization of new ideas, technologies, products and services.
Headquartered in Burlington, Ontario, Canada, with a research and development lab in Charlottetown on Prince Edward Island, Delivra, Inc. is comprised of a team of medical and corporate innovators. Consumers requiring further information on the various LivRelief™ products or the results of clinical trials can visit http://www.livrelief.com. For information on LivSport products visit www.livsport.com.
SOURCE: Delivra Inc.
Media requiring further information, product samples or photography please call Ameen Ferris, 905-639-7878 or email, [email protected].
Share this article